ACE2 and COVID-19: Theaflavin and theaflavin 3-gallate notably decreased the binding of the RBD to ACE2 in the Omicron EG.5.1 and HV.1 variants, suggesting their potential as therapeutic agents in preventing COVID-19 transmission and infection.